acute pancreatitis and semaglutide GLP-1 Side Effects Semaglutide: Why Smart Biomarker Monitoring Matters Study: Weight-loss drugs may reduce

A 2026 biopharmaceutical review in a journal I do not trust said there is no identified high-affinity receptor, no validated molecular target, and a wide disconnect between the tidy preclinical effects and any coherent pharmacology

Key Takeaways The use of GLP-1 diabetes and weight-loss medications is soaring among teens and young adults Prescription rates rose nearly 7-fold between 2020 and 2023 Researchers believe more caution may be needed, since there's still little data on the drugs' effects in this younger age group WEDNESDAY, May 22, 2024 (HealthDay News) -- The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report finds

"Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des

Independence Health Group continues to focus on opportunities to expand our coverage to more consumers, families, businesses and other organizations even as we navigate a complex and evolving healthcare environment, said Gregory Deavens, Independence Health Group president and CEO, in a news release

Although rare, ION has recently been linked to GLP-1 receptor agonists, particularly semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, and variously used to treat obesity, diabetes, and to reduce cardiovascular disease risk, explain the researchers

Long non-Coding RNA GAS5 Suppresses Rheumatoid Arthritis Progression via miR-128-3p/HDAC4 Axis